SEARCH OUR PAGES

Products

Products

Our pipeline
Delivering first-in-class immunotherapies
of activation and regulation

OSE Immunotherapeutics’ team has unique expertise and experience in immunological target discovery that serves as the basis for the development of innovative agonists and antagonists for application in immuno-oncology and autoimmune diseases.

We have already developed several first-in-class products that activate or regulate the immune system and cover a wide range of clinical indications, generating several academic and pharma partnerships.

OSE Immunotherapeutics’ pipeline is currently comprised of six developmental projects, four in immuno-oncology and two in autoimmune diseases. Five of our candidates are currently in the clinic.

Program
Indication
Humanized
lead
Pre-Clinical
POC
Phase 1
Phase 2
Phase 3
Partners
Immuno-oncology
Tedopi®
Neo-Epitopes
NSCLC
Positive Step-1 results; primary endpoint met
Tedopi®
Neo-Epitopes
Advanced pancreatic cancer
Combo with PD1 Opdivo® ongoing
BI 765063 (OSE-172)
SIRPα
Advanced solid tumours
Ongoing
OSE-703
IL-7 R
Various cancers
2020
BiCKI®
Bi-specific anti-PD-1 & Innovative targets
Various cancers
2020

Program

  • Indication NSCLC
  • Humanized
  • Pre-Clinical POC
  • Phase 1
  • Phase 2
  • Phase 3 Positive Step-1 results; primary endpoint met
  • Partners
  • Indication Advanced pancreatic cancer
  • Humanized
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 Combo with PD1 Opdivo® ongoing
  • Phase 3
  • Partners
  • Indication Advanced solid tumours
  • Humanized
  • Pre-Clinical POC
  • Phase 1 Ongoing
  • Phase 2
  • Phase 3
  • Partners
  • Indication Various cancers
  • Humanized
  • Pre-Clinical POC 2020
  • Phase 1
  • Phase 2
  • Phase 3
  • Partners
  • Indication Various cancers
  • Humanized
  • Pre-Clinical POC 2020
  • Phase 1
  • Phase 2
  • Phase 3
  • Partners
Program
Indication
Humanized
lead
Pre-Clinical
POC
Phase 1
Phase 2
Phase 3
Partners
Auto-immune diseases
FR104
CD-28
Auto-immune diseases & Transplantation
Phase 2 planning ongoing
OSE-127
IL-7 R
UC Sjögren
Positive Phase 1 results Q4 2019
2020

Program

  • Indication Auto-immune diseases & Transplantation
  • Humanized
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 Phase 2 planning ongoing
  • Phase 3
  • Partners
  • Indication UC Sjögren
  • Humanized
  • Pre-Clinical POC
  • Phase 1 Positive Phase 1 results Q4 2019
  • Phase 2 2020
  • Phase 3
  • Partners